Compare BridgeBio Pharma Inc (BBIO) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs State Street SPDR S&P Homebuilders ETF — how do they compare? BridgeBio Pharma Inc trades at $82.87 (market cap $16.46B), while State Street SPDR S&P Homebuilders ETF trades at $108.59. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | XHB | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $90.17 | $121.36 |
52-Week Low | $44.81 | $94.86 |
Enterprise Value | $18.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
XHB trades at $107.07, down 1.42% amid bearish technical signals, with support at $104 and resistance at $110. The ETF faces mixed housing data with declining existing home sales but potential tailwinds from new housing legislation. Key indicators show oversold short-term RSI but strong bearish momentum from ADX.
Outlook is cautious due to high mortgage rates and record home prices pressuring demand, though legislative support for homebuilders offers upside. Risks include interest rate sensitivity and economic slowdowns. Analyst sentiment is neutral with focus on housing market recovery timing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
